NCT04787965View on ClinicalTrials.gov

Opicapone Treatment Initiation Open-Label Study

CompletedOBSERVATIONAL
Enrollment

239

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

August 4, 2022

Study Completion Date

August 4, 2022

Conditions
Parkinson Disease
Interventions
DRUG

Opicapone

Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period

Trial Locations (6)

24073

Neurocrine clinical site, Christiansburg

25827

Neurocrine clinical site, Crab Orchard

38157

Neurocrine clinical site, Memphis

68134

Neurocrine clinical site, Norfolk

95032

Neurocrine clinical site, Los Gatos

98002

Neurocrine clinical site, Auburn

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY